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Summary
Background The aim of this systematic review was
to update scientific knowledge concerning the safety
of neuromuscular electrical stimulation (NMES) to in-
crease exercise capacity and prevent cardiac cachexia
in patients with implantable cardioverter defibrillators
(ICDs).
Methods A systematic review including the elec-
tronic databases PubMed, MEDLINE, and SCOPUS
was conducted for the time period from 1966 to
March 31, 2016.
Results Only four articles fulfilled the inclusion crite-
ria (three original articles/safety studies and one case
report). The three (safety) studies used NMES to in-
crease muscle strength and/or endurance capacity of
the thighs. NMES did not show electromagnetic inter-
ference (EMI) with ICD function. EMI was described
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in a case report of 2 patients with subpectoral ICDs
and application of NMES on abdominal muscles.
Conclusion This review indicates that NMES may be
applied in cardiac ICD patients if 1) individual risks
(e. g., pacing dependency, acute heart failure, unsta-
ble angina, ventricular arrhythmic episode in the last
3 months) are excluded by performing a safety check
before starting NMES treatment and 2) “passive” ex-
ercise using NMES is performed only for thighs and
gluteal muscles in 3) compliant ICD patients (espe-
cially for home-based NMES) and 4) the treatment is
regularly supervised by a physician and the device is
examined after the first use of NMES to exclude EMI.
Nevertheless, further studies including larger sample
sizes are necessary to exclude any risk when NMES is
used in this patient group.
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Introduction
Typical symptoms of severe congestive chronic heart
failure (CHF) are dyspnea, edema, weakness, and re-
duced functional capacity of skeletal muscles, which
can result in cardiac cachexia [1–4]. Cardiac cachexia
is a serious complication of CHF with a high morbid-
ity and mortality, and is characterized by significant
weight loss and muscle wasting [1, 2]. CHF-related
muscle wasting is the result of an ongoing imbalance
in the activation of anabolic and catabolic pathways
[3, 5, 6]. This imbalance is caused by a series of
immunologic, metabolic, and neuro-hormonal pro-
cesses [2, 6, 7]. Efficient multidisciplinary care seems
to be pivotal for disease management in this patient
group [8].
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Muscular strength of the thighs has been shown to
be a predictor of long-term survival in CHF [1, 9, 10].
Patients with advanced CHF (New York Heart Associ-
ation, NYHA, class IV) are generally excluded from
active exercise to maintain muscle mass and func-
tional capacity of skeletal muscle, namely endurance
capacity and muscular strength [1, 10]. The physical
treatment modality of neuromuscular electrical stim-
ulation (NMES)—evoking muscle contractions by us-
ing electrical stimulation—is an established method
to prevent atrophy of skeletal muscles [11–13]. It can
be seen as an alternative option to active endurance
and strength exercise for patients who are not allowed
(contraindication) or unable (immobilization) to per-
form active exercise [14–17]. NMES leads to improve-
ments in endurance capacity, muscular strength, and
cross-sectional area of thigh muscles in patients with
CHF, and has therefore been shown to be an effective
option for “passive” exercise in these patients [17–19].
NMES has been described to effectively substitute,
promote, or complement active exercise and increase
adherence to rehabilitation protocols, especially for
end-stage cardiac patients [17, 20]. Nevertheless, de-
spite its benefits for exercise capacity and quality of
life, NMES is currently underutilized in patients with
CHF [21].
However, about 20 percent of CHF patients carry
active electronic implants such as implantable car-
dioverter defibrillators (ICDs). Therefore, there is an
existing and remaining concern of whether NMES can
be applied in these patients, due to fear of electro-
magnetic interference (EMI). EMI can cause oversens-
ing and lead to inappropriate therapies in ICD pa-
tients, resulting in arrhythmias and/or painful shocks
[22–24]. These patients are generally advised to avoid
exposure to electrical currents and electromagnetic
sources, even though ICDs seem to be less sensitive
to interference than pacemakers [25].
Pilot safety studies performed at the beginning of
this century, designed to test the safety of NMES in
patients with bipolar sensing by ICD lead systems,
have shown that NMES treatment of knee extensor
and flexor muscles seems to be safe and feasible in
patients with bipolar sensing ICDs, providing that an
individual risk is excluded before application [26, 27].
Nevertheless, several reports exist of inappropriate
therapies/shocks due to interactions with electronic
devices or electrical stimulation therapy leading to
EMI [28–30].
This review aims to summarize and update knowl-
edge from the scientific literature concerning NMES
of thighs in ICD patients.
Methods
A systematic review of the existing scientific literature
was performed, including the electronic databases
PubMed, MEDLINE, and SCOPUS. Electronic searches
were conducted for the time period from 1966 to
March 31, 2016. Trials with the keywords “Implanted
Cardioverter Defibrillator”, “ICD”, “Neuromuscular
stimulation”, “NMES”, “Functional electrical stimula-
tion”, “FES”, and “Functional muscular stimulation”
were extracted and considered for inclusion in the
review. Furthermore, the combinations “Physical
therapy and ICD and EMI” and “Physical therapy and
ICD and Interference”, were also checked for inclusion
in the review.
Studies were eligible for inclusion if they met the
following criteria: original articles/safety studies, pi-
lot studies, case reports, and reviews concerning the
topic NMES in ICD patients were included. The re-
striction placed on language was that only English
and German articles were included. The systematic
literature search was performed separately by two in-
dependent researchers. Integration of their individ-
ual findings was supervised by two senior researchers
[31, 32]. Author searches for key experts in the field
were conducted for additional relevant articles. Fur-
thermore, reference lists of each relevant publication
were searched for additional information.
Results
Using the described search strategy, a total of 725 pub-
lications were found and screened for eligibility by ti-
tle and abstract. 721 were rejected as non-includable
or duplicates, and four studies were selected for full-
text analysis (Fig. 1).
Of these, four fulfilled the inclusion criteria of be-
ing:
● Original articles (full text available in English orGer-
man),
● Safety studies, pilot studies, case reports, or reviews.
Studies were excluded because of the following crite-
ria:
● Full text not available in English or German,
● Reporting an intervention using transcutaneous
electrical nerve stimulation (TENS, for treatment of
pain) or other currents for analgesia, but no NMES.
Case report
Wayar et al. reported on two male patients with pec-
toral implanted ICDs (Ventak Mini III® and Ventak
AV III DR®) and neuromuscular stimulation of ab-
dominal muscles [33]. In both patients, NMES using
commercial units (5.0–11.0 V, 7.3–10 mA, 55–75 Hz/
biphasic) provoked EMI, resulting in ICD discharge
due to misinterpreting electrical signals as cardiac sig-
nals in the ventricular fibrillation (VF) zone (Table 1;
[33]).
Safety studies
Crevenna et al. performed the first safety study [27].
Eight patients had subpectorally implanted ICDs with
transvenous bipolar sensing leads and received dif-
ferent types (different current forms) of electrical
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Literature search:
1. Databases: PubMed, MEDLINE, SCOPUS
2. Articles published between 1966 and March 2016
3. Search results: 725
4 included publications:
1. Full text available in English or German
2. Original articles, safety studies, pilot studies, case 
reports or reviews
721 excluded publications:
• Full text not in English or German
• Reporting an intervention by using transcutaneous 
electrical nerve stimulation (TENS, for treatment of 
pain) or other currents for analgesia, but no NMES-
intervention
Fig. 1 Flowchart of the systematic literature researchand the
selectionprocess
stimulation of trapezoid and thigh muscles, namely
impulse galvanization (IG50); frequency modulation
(FM); high-frequency transcutaneous electrical nerve
stimulation (HF-TENS) and low-frequency transcu-
taneous electrical nerve stimulation (LF-TENS) of
trapezoid muscles; “E200” (impulses of a rise dura-
tion of 200 ms and pulse duration of 270 ms at a fre-
quency of 0.44 Hz); “aS” (pulse duration of 400 µs with
a threshold duration of approximately 6.5 s at a fre-
quency of 66.7 Hz); “aS1” (pulse duration of 400 µs
and a threshold duration of 3.6 Hz at a frequency
of 66.7 Hz); and a (specially programmed) electri-
cal current (“FIB”) comprising triangular impulses
over 60 ms with an interval of 200 ms, mimicking
an episode of tachycardia in the ICD detection zone.
Furthermore, two different commercially available
devices for home therapy for increasing endurance
capacity (Stiwell 1200 (Med-El, Innsbruck, Austria)
and Compex 2 [Compex SA, Ecublens, Switzerland])
were tested.
The results showed that electrical stimulation was
well tolerated in all participants and no clinical side
effects were reported. No interference with ventricular
sensing during electrical stimulation was seen in 5 of
8 patients. No EMI was caused upon stimulating the
thigh musculature using home therapy devices or dur-
ing stimulation protocols “E200”, “aS”, or “aS1”. Mim-
icking a tachycardia by using “FIB” to thigh muscles
was enforced in 2 patients. EMI of ventricular sensing
was also caused by stimulating trapezoidmuscles dur-
ing FM in 1 patient and during LF-TENS in 2 patients.
The authors advise investigating EMI before starting
NMES in patients with ICDs (Table 1; [27]).
In another study, Crevenna et al. assessed the safety
of long-term NMES in patients with ICDs [26]. Six
patients with subpectoral ICDs were exposed to long-
term NMES of thigh muscles. Four inpatients received
NMES to increase muscle strength (biphasic symmet-
ric pulses with pulse duration of ±400 ms at a fre-
quency of 63.3 Hz; 3.5 s on, 4.5 s off). Two outpatients
performed NMES as home treatment to increase en-
durance capacity (biphasic symmetric pulses of 500-
ms pulse width at a frequency of 15 Hz; 2 s on and 4 s
off). During NMES, all participants together received
14,139,799 biphasic electrical pulses and 412,425 on-
phases without adverse events. No abnormalities of
ICD function were recorded after the stimulation pe-
riod in any patients. In a safety procedure, NMES
was applied under supervised conditions to evaluate
the individual risk. Symptom-limited NMES was per-
formed and the ICD was interrogated online for po-
tential occurrences of EMI. The results of this indi-
cated that long-term NMES of thigh muscles seems
to be safe in patients with ICDs, providing that an
individual risk was excluded prior to start of NMES
therapy (Table 1; [26]).
Kamiya et al. recently performed a safety study
with NMES in 27 patients with left pectoral ICDs [34].
Medium-frequent NMES of knee flexors and exten-
sors with alternating sinusoidal current (2.5 kHz) for
20 minutes in bursts with a carrier frequency of 50 Hz
and impulse trains for 5 s and pauses for 5 s was used
at individual highest tolerable intensities. In this case,
NMES of thighmuscles was applied to the participants
without any occurrence of EMI. Additionally, EMI be-
tween ICDs and NMES application was not observed.
The authors therefore concluded that NMES of thigh
and calf musculature can be safely applied to patients
with an ICD (Table 1; [34]).
Discussion
Muscular strength of thighs has been shown to be
a predictor of long-term survival in CHF [1, 9, 10].
As Parissis et al. have summarized, functional electri-
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Table 1 Summaryof publicationsconcerningneuromuscular electrical stimulation in cardiacpatientswith implantable car-
dioverter defibrillators
























50 Hz, biphasic, 20 min, burst,
2.5 kHz, 5 s stim. +5 s interval,
highest tolerable intensity (thigh:
25–60 mA; calf: 15–40 mA)

















NMES of thigh muscles –4 patients: 63.3 Hz, 3.5 s on
+4.5 s off, biphasic, 55–100 mA
–2 patients: 15 Hz, 2 s on +4 s
off, biphasic, 500 ms pulse width




Safety study (n = 8) Subpectoral ICDs:
– ELA 9201®












– IG 50, FM, HF TENS,
LF TENS of trape-
zoid muscle
– E200, aS, aS1, FIB
of thigh muscles
– IG50: dir. cur., 128 mA,
200 Hz, 400 μs stim. + serial
duration of 50 ms
– FM: 3.33–33.3 Hz, 400 μs
alternated by tetanizing impulse
effects
– HF-TENS: 100 Hz, 200 μs stim.
– LF-TENS: 2 Hz, 200 μs stim.
– E200: 200 ms rise +270 ms
pulse dur., 0.44 Hz;
– aS: 400 μs pulse dur. +6.5 s
thresh. dur., 66.7 Hz
– aS1: 400 μs pulse dur. +3.6 s
thresh. dur., 66.7 Hz
– FIB: 60 ms impulse with an
interval of 200 ms;
– Home treatment devices:
– biphasic, 500 μs impulse,
15 Hz, 2 s pulse dur.
– biphasic, 250 μs impulse,
8/15/30 and 50 Hz, 1 s rise
time, steady impulse over 8 s,
1 s fall time
EMI caused by
– FM in 1 patient
– LF TENS in 2 patients
– FIB in 2 patients
Neck stimulation: FM stimulation
in 1 patient/LF TENS in 2 patients:
EMI of ventricular sensing/atrial
sensing.
Thigh stimulation:
FIB: EMI in 2 patients and inter-
mittent ventricular undersensing
due to postsense
EMI did not fulfill ICD detection
criteria of a tachyarrhythmic
ventricular episode in any of the
subjects under study blanking in
1 of these participants.




Case report (n = 2) 1st patient: pectoral
ICD (Ventak® Mini





55–75 Hz, biphasic, 7.3–10 mA,
5–11 V
EMI in both patients
2nd patient: pec-
toral ICD (Ventak®
AV [Guidant Inc., St.
Paul, Minnesota,
USA])
ICD implantable cardioverter defibrillator, NMES neuromuscular electrical stimulation, stim stimulation, EMI electromagnetic interference, IG50 Impulse
galvanization, dir. cur. direct current, FM frequency modulation, HF-TENS high frequency transcutaneous electrical nerve stimulation, LF-TENS low frequency
transcutaneous electrical nerve stimulation, FIB mimics tachycardia, thresh. dur. threshold duration, Stiwell 1200 (Med-El, Innsbruck, Austria) and Compex 2
(Compex SA, Ecublens, Switzerland) home devices
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cal stimulation of thighs and calf muscles is the only
alternative mode of exercise in patients with CHF [18].
Literature about NMES in patients with ICDs is very
rare. The reason for this seems to be that ICDs are
generally seen as a contraindication for the use of
NMES by the community. Nevertheless, NMES has
been described to be an effective and safe treatment
option for ICD patients provided certain safety pre-
cautions are considered [26, 27, 34]. In the scientific
literature, there are only four articles describing the
safety of NMES in patients with pectoral ICDs. Three
of them showed the safety of NMES when applied to
lower extremities in order to improve muscle strength
and endurance capacity [26, 27, 34]. Crevenna et al.
reported feasibility and safety of NMES in ICD pa-
tients if individual risks were checked prior to treat-
ment initiation [26, 27].
In contrast, inappropriate electrode positioning for
NMES can provoke disturbances of ICDs [33]. In one
study, 2 patients autonomously applied the stimula-
tion too close to the implantation site of the pectoral
ICD, namely to the abdominal musculature, caus-
ing discharge of the ICD by signals in the VF zone
[33]. Nevertheless, at that time, ICD programming
had usually been very strict, e. g., short detection of
VF and shock delivery at the first stage in the VF
zone. Nowadays, prolonged detection programming
and shock delivery only if antitachycardia pacing etc.
fail may prevent many inappropriate shocks. There-
fore, it might be doubtful that modern ICDs can be
disturbed by NMES in the abdominal region. Nev-
ertheless, further studies are needed to answer this
question.
Unfortunately, the terms TENS (for pain treatment)
and NMES are not clearly distinguished by all pub-
lishing authors. TENS is a non-pharmacologic treat-
ment for pain relief, applied in the form of low-fre-
quency (<12 Hz) or high-frequency TENS (50–100 Hz).
Some case reports present discharge of pectoral or ab-
dominal ICDs in patients during use of TENS for pain
treatment in the lumbar, trapezoidal, and abdominal
musculature, or chest or midback area [27–30, 35]. In
another case report, TENS of the sacral region pro-
voked an ICD discharge, although the electrodes were
12 inches away from the ICD pulse generator [36]. In
an exploratory study, 30 patients with implanted de-
fibrillators (ICDs) underwent TENS treatment above
the mammillae and the anterior superior iliac spine
after programming the ICD to monitoring mode. Due
to possible consequences of inexact sensing, the au-
thors do not advise the application of TENS in pa-
tients with an ICD [37]. Pain management using elec-
trotherapy, e. g., TENS, is substituted by pharmacolog-
ical treatment and should be avoided in patients with
ICDs.
Options to improvemuscle strength and endurance
capacity in patients with end-stage heart failure are
rather limited. In most cases, patients with CHF are
discouraged from performing active exercise to main-
tain muscle mass and functional capacity of skele-
tal muscle, namely endurance capacity and muscu-
lar strength [1, 11]. In Austria, NMES treatment of
patients suffering from chronic diseases has a long
tradition [17, 20, 26, 27, 38–42]. Depending on the
exercise goal, different commercially available ther-
apy devices are used with direct or alternating current
(biphasic) between 8–63.3 Hz, and, according to this,
adjustable pulse durations and session length (usually
20–30 min).
This systematic review of existing scientific litera-
ture indicates that NMES treatment of thigh muscles
seems to be safe and feasible in CHF patients with
bipolar ICDs. Nevertheless, risk analyses to detect
harmful events require a large sample size in order
to arrive at valid predictions for the community, and
such high powered and large safety studies are yet to
be realized. We therefore conclude that NMES can be
performed in cardiac ICD patients if 1) individual risks
(e. g., pacing dependency, acute heart failure, unsta-
ble angina, ventricular arrhythmic episode in the last
3 months) are excluded by performing a safety check
before starting NMES treatment and 2) “passive” ex-
ercise using NMES is performed only for thighs and
gluteal muscles in 3) compliant ICD patients (espe-
cially for home-based NMES) and 4) the treatment is
regularly supervised by a physician and the device is
examined after the first use of NMES to exclude EMI.
Nevertheless, further studies including larger sample
sizes are necessary to exclude any risk when NMES is
used in this patient group.
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